QURE - ユニキュア （uniQure N.V.） ユニキュアQUREのチャート
QUREの企業情報
| symbol | QURE |
|---|---|
| 会社名 | uniQure N.V. （ユニキュア） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships. The Company’s product candidates within the Core Program include AMT-061 for Hemophilia B AMT-130 for Huntington's disease and S100A1 for congestive heart failure. The Company through its collaboration with Bristol Myers-Squibb (BMS) is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure. ユニキュアは、オランダの遺伝子治療製品メ―カ―。遺伝子治療は、単回投与を通じて不足しているタンパク質の発現を誘導・復元することによって遺伝的または後天性疾患の患者への治癒を目指すもので、同社製品Glyberaは、リポ蛋白質リパ―ゼ欠損症の患者の治療薬で欧州地域で初めて承認された遺伝子治療薬。 uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. |
| 本社所在地 | Paasheuvelweg 25A Amsterdam 1105 BP NLD |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +31 20-240-6000 |
| 設立年月日 | 40909 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 202人 |
| url | www.uniqure.com |
| nasdaq_url | https://www.nasdaq.com/symbol/qure |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -65.82200 |
| 終値（lastsale） | 29.11 |
| 時価総額（marketcap） | 1084428629.57 |
| 時価総額 | 時価総額（百万ドル） 993.90440 |
| 売上高 | 売上高（百万ドル） 11.37200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 755.59240 |
| 当期純利益 | 当期純利益（百万ドル） -78.80000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Uniqure NV revenues decreased 21% to $6.5M. Net loss decreased 5% to $39.4M. Revenues reflect Collaboration revenues decrease from $4.6M to $0K License revenues decrease from $8K to $0K. Lower net loss reflects Foreign currency (losses) / gains net increase from $1.2M (expense) to $2.4M (income) Other expense decrease of 71% to $762K (expense) Interest Income increase from $23K to $836K (income). |
QUREのテクニカル分析
QUREのニュース
uniQure (QURE) Investor Presentation - Slideshow 2023/03/10 13:28:45 Seeking Alpha
The following slide deck was published by uniQure N.V.
uniQure Stock Trying To Close In On Key Technical Measure 2023/02/28 21:19:00 Investor''s Business Daily
A Relative Strength Rating upgrade for uniQure shows improving technical performance. Will it continue?
uniQure GAAP EPS of -$2.71 beats by $0.98, revenue of $106.48M beats by $83.27M 2023/02/27 12:39:16 Seeking Alpha
uniQure press release (QURE): FY GAAP EPS of -$2.71 beats by $0.98.Revenue of $106.48M (-79.7% Y/Y) beats by $83.27M.As of December 31, 2022, the Company had cash and cash…
uniQure Inc.: uniQure Announces 2022 Financial Results and Highlights Recent Company Progress 2023/02/27 12:10:00 Finanz Nachrichten
~ Achieved U.S. and European Commission marketing approvals of first and only gene therapyfor adults with hemophilia B ~ ~ Advancing development of AMT-130 for patients with Huntington''s disease - …
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress 2023/02/27 12:05:00 GlobeNewswire
~ Achieved U.S. and European Commission marketing approvals of first and only gene therapy for adults with hemophilia B ~
uniQure N.V.: Two Possible Regulatory Approvals Makes This A Must Watch (NASDAQ:QURE) 2022/08/30 18:26:29 Seeking Alpha
Potential U.S. and European approvals possible of etranacogene dezaparvovec for treatment of Hemophilia B before end of 2022 and early 2023 respectively.
US stock market closed mixed, Dow Jones up 0.09% 2022/08/09 03:36:37 InstaForex
At the close of the New York Stock Exchange, the Dow Jones rose 0.09%, the S&P 500 fell 0.12%, and the NASDAQ Composite fell 0.10%. The leading performer among the components of the Dow Jones index today was Walt Disney Company, which gained 2.48 points or 2.33% to close at 109.11. Quotes Dow Inc rose by 0.66 points (1.28%), ending trading at 52.15. Walgreens Boots Alliance Inc rose 0.49 points or 1.26% to close at 39.48. The biggest losers were JPMorgan Chase & Co, which shed 1.41 points or 1.22% to end the session at 114.35. Visa Inc Class A was up 2.55 points (1.18%) to close at 213.32, while McDonald''s Corporation was down 2.43 points (0.94%) to close at 256. .80. Leading gainers among the S&P 500 index components in today''s trading were Penn National Gaming Inc, which rose 5.56% to hit 36.05, Gap Inc, which gained 5.44% to close at 10.27, and also shares of General Motors Company, which rose 4.16% to close the session at 37.56. The biggest losers were Tyson Foods Inc, which shed 8.40% to close at 80.10.
Why uniQure Stock Is Crashing Today 2022/08/08 15:53:50 The Motley Fool
The company is temporarily delaying higher-dose procedures of experimental gene therapy AMT-130.
Why UniQure Shares Are Plummeting Today? 2022/08/08 15:50:47 Benzinga
Tucked in its Q2 earnings release , UniQure N.V. (NASDAQ: QURE ) said that in July, it had observed suspected, unexpected severe adverse reactions (SUSARs) in two patients after they were treated with the "higher dose" of AMT-130 in a European Phase 1b/2 trial. AMT-130 is a gene therapy candidate for Huntington''s disease. A third patient treated back in … Full story available on Benzinga.com
CinCor, Karuna top healthcare gainers; Reata, uniQure lead losers'' pack 2022/08/08 14:04:14 Seeking Alpha
CinCor Pharma CINC +66%. Karuna Therapeutics KRTX +61%. Reata Pharmaceuticals RETA -31%. uniQure QURE -23%.
uniQure GAAP EPS of -$1.00 misses by $0.20, revenue of $1.79M misses by $0.67M 2022/05/02 11:20:19 Seeking Alpha
uniQure press release (QURE): Q1 GAAP EPS of -$1.00 misses by $0.20.Revenue of $1.79M (+297.8% Y/Y) misses by $0.67M.As of March 31, 2022, the Company had cash and cash equivalents…
uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress 2022/05/02 11:05:00 GlobeNewswire
~ Partner CSL Behring submitted Marketing Authorization Application (MAA) in Europe for etranacogene dezaparvovec in hemophilia B; MAA validated by the European Medicines Agency (EMA) and granted accelerated assessment ~
uniQure N.V. (NASDAQ:QURE) Drops -3.36%, But A Strong Recovery May Be Imminent 2022/04/30 11:00:00 Marketing Sentinel
In last trading session, uniQure N.V. (NASDAQ:QURE) saw 0.48 million shares changing hands with its beta currently measuring 1.05. Company’s recent per share price level of $14.94 trading at -$0.52 or -3.36% at ring of the bell on the day assigns it a market valuation of $749.09M. That closing price of QURE’s stock is at … uniQure N.V. (NASDAQ:QURE) Drops -3.36%, But A Strong Recovery May Be Imminent Read More »